Kintsugi Closes After Failing to Secure FDA Approval for AI Tech
Kintsugi, a California-based startup, has announced its closure after failing to obtain approval from the U.S. Food and Drug Administration (FDA) for its AI technology designed to detect signs of depression and anxiety through speech analysis. The company plans to release most of its technologies as open-source, allowing for use in other fields.